Form 4: Amicus Therapeutics CEO Sells Shares Post-Option Exercise

Amicus Therapeutics CEO Bradley L. Campbell exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Bradley L. Campbell, President and CEO of Amicus Therapeutics, engaged in transactions involving the company's common stock.
• On November 24, 2025, Mr. Campbell exercised 14,587 stock options at an exercise price of $9.03 per share.
• Immediately following the exercise, Mr. Campbell sold 14,587 shares of common stock at a weighted average price of $10.0447 per share.
• The sale prices for the transactions ranged from $10.00 to $10.17 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Campbell on September 13, 2024.
• Following these transactions, Mr. Campbell beneficially owns 1,137,282 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan, which is generally considered neutral for company sentiment.

Positives

• The stock options exercised were fully vested and exercisable as of the transaction date.
• The sale price of $10.0447 per share was higher than the exercise price of $9.03 per share, indicating a profitable transaction for the insider.

Negatives

• Insider selling, even under a pre-arranged plan, can sometimes be perceived by some investors as a lack of confidence, though this is not explicitly stated or implied by the filing itself.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the CEO's direct ownership percentage, though the transaction was pre-scheduled under a 10b5-1 plan, which typically mitigates negative perceptions of insider selling.

Key Dates

Recommendation

The filing details a pre-scheduled insider transaction (option exercise and sale) by the CEO, which is a routine event and does not provide sufficient new information to alter an investment recommendation. The transaction was executed under a Rule 10b5-1 plan, mitigating concerns typically associated with unscheduled insider selling.

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Options, CEO, Bradley L. Campbell, 10b5-1 Plan, Equity Sales